Gilead Sciences (GILD) PT Raised to $134 at Piper Jaffray on Another 'Beat and Raise'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Gilead Sciences' (GILD) Price Target Bumped to $135 at Deutsche Bank
July 29, 2015 10:13 AM EDTDeutsche Bank maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $135.00 (from $125.00). Analyst Robyn Karnauskas characterized Q2 results as "solid" and said HCV discounts don't look bad.
"We are lowering our US HCV revenues while increasing OUS numbers & model WW revs at $18.5B vs.... More
Gilead Sciences (GILD) PT Lifted to $135 at Baird on Strong Earnings Beat
July 29, 2015 6:58 AM EDTBaird analyst Brian Skorney lifted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $135.00 (from $126.00) following earnings beat.
Skorney commented, "Gilead handily beat expectations, across the board, and raised revenue guidance yet again. Interestingly, nothing in Hep C declined... More
Gilead Sciences (GILD) PT Raised to $120 at Oppenheimer on Solid Q2 Beat
July 29, 2015 6:28 AM EDTOppenheimer analyst Wendy Lam reiterated an Outperform rating and boosted her price target on Gilead Sciences (NASDAQ: GILD) to $120.00 (from $86.00) following solid the Q2 beat.
Lam commented, "GILD reported a healthy 2Q15 EPS and product revenues beat ($3.15/$8.13B vs. $2.71/$7.60B consensus) underpinned by... More
Gilead Sciences (GILD) Tops Q2 EPS by 44c
July 28, 2015 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q2 EPS of $3.15, $0.44 better than the analyst estimate of $2.71. Revenue for the quarter came in at $8.24 billion versus the consensus estimate of $7.61 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
... More